Review Article| Volume 18, ISSUE 2, P215-221, April 2023

Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment

Actinium-225-DOTATATE and Combined Therapies


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to PET Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Xu Z.
        • Wang L.
        • Dai S.
        • et al.
        Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States.
        JAMA Netw Open. 2021; 4: e2124750
        • Nagtegaal I.D.
        • Odze R.D.
        • Klimstra D.
        • et al.
        The 2019 WHO classification of tumours of the digestive system.
        Histopathology. 2020; 76: 182-188
        • Uri I.
        • Grozinsky-Glasberg S.
        Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
        Clin Diabetes Endocrinol. 2018; 4: 16
        • Cives M.
        • Strosberg J.R.
        Gastroenteropancreatic neuroendocrine tumors.
        CA Cancer J Clin. 2018; 68: 471-487
        • Rinke A.
        • Gress T.M.
        Neuroendocrine cancer, therapeutic strategies in G3 cancers.
        Digestion. 2017; 95: 109-114
        • Hofman M.S.
        • Lau W.E.
        • Hicks R.J.
        Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.
        Radiographics. 2015; 35: 500-516
        • Van Der Zwan W.A.
        • Bodei L.
        • Mueller-Brand J.
        • et al.
        GEP–NETs Update: radionuclide therapy in neuroendocrine tumours.
        Eur J Endocrinol. 2015; 172: R1-R8
        • Strosberg J.
        • El-Haddad G.
        • Wolin E.
        • et al.
        Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumours.
        N Engl J Med. 2017; 376: 125-135
        • Strosberg J.R.
        • Caplin M.E.
        • Kunz P.L.
        • et al.
        177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
        Lancet Oncol. 2021; 22: 1752-1763
        • Kratochwil C.
        • Giesel F.L.
        • Heussel C.P.
        • et al.
        Patients resistant against PSMA-targeting α-radiation therapy often harbor mutations in DNA damage-repair-associated genes.
        J Nucl Med. 2020; 61: 683-688
        • Tafreshi N.K.
        • Doligalski M.L.
        • Tichacek C.J.
        • et al.
        Development of targeted alpha particle therapy for solid tumors.
        Molecules. 2019; 24: 4314
        • Basu S.
        • Parghane R.V.
        • Kamaldeep
        • et al.
        Peptide receptor radionuclide therapy of neuroendocrine tumors.
        Semin Nucl Med. 2020; 50: 447-464
        • Zhang J.
        • Liu Q.
        • Singh A.
        • et al.
        Prognostic value of 18F-FDG PET/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy.
        J Nucl Med. 2020; 61: 1560-1569
        • Chan D.L.
        • Pavlakis N.
        • Schembri G.P.
        • et al.
        Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.
        Theranostics. 2017; 7: 1149-1158
        • Chan H.S.
        • de Blois E.
        • Morgenstern A.
        • et al.
        In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
        PLoS One. 2017; 12: e0181473
        • Graf F.
        • Fahrer J.
        • Maus S.
        • et al.
        DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
        PLoS One. 2014; 9: e88239
        • Miederer M.
        • Henriksen G.
        • Alke A.
        • et al.
        Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
        Clin Cancer Res. 2008; 14: 3555-3561
        • Ballal S.
        • Yadav M.P.
        • Bal C.
        • et al.
        Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety.
        Eur J Nucl Med Mol Imaging. 2020; 47: 934-946
        • Ballal S.
        • Yadav M.P.
        • Tripathi M.
        • et al.
        Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study.
        J Nucl Med. 2022;
        • Kratochwil C.
        • Apostolidis L.
        • Rathke H.
        • et al.
        Dosing 225Ac-D122.264043. OTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.
        Eur J Nucl Med Mol Imaging. 2021; 49: 54-63
        • Kavanal A.J.
        • Satapathy S.
        • Sood A.
        • et al.
        Subclinical hypothyroidism after 225Ac-DOTATATE therapy in a case of metastatic neuroendocrine tumor: unknown adverse effect of PRRT.
        Clin Nucl Med. 2022; 47: e184-e186
        • Satapathy S.
        • Sood A.
        • Das C.K.
        • et al.
        Alpha before beta: exceptional response to first-line 225Ac-DOTATATE in a patient of metastatic neuroendocrine tumor with extensive skeletal involvement.
        Clin Nucl Med. 2022; 47: e156-e157
        • Delpassand E.S.
        • Tworowska I.
        • Esfandiari R.
        • et al.
        Targeted alpha-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-human, dose-escalation clinical trial.
        J Nucl Med. 2022; 121 (jnumed): 263230
        • Thang S.P.
        • Lung M.S.
        • Kong G.
        • et al.
        Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) – a single-institution retrospective analysis.
        Eur J Nucl Med Mol Imaging. 2017; 45: 262-277
        • Zhang J.
        • Kulkarni H.R.
        • Singh A.
        • et al.
        Peptide receptor radionuclide therapy in Grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients.
        J Nucl Med. 2019; 60: 377-385
        • Carlsen E.A.
        • Fazio N.
        • Granberg D.
        • et al.
        Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
        Endocr Relat Cancer. 2019; 26: 227-239
        • Rich T.A.
        • Shepard R.C.
        • Mosley S.T.
        Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.
        J Clin Oncol. 2004; 22: 2214-2232
        • Van Essen M.
        • Krenning E.P.
        • Kam B.L.
        • et al.
        Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
        Eur J Nucl Med Mol Imaging. 2008; 35: 743-748
        • Hubble D.
        • Kong G.
        • Michael M.
        • et al.
        177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
        Eur J Nucl Med Mol Imaging. 2010; 37: 1869-1875
        • Claringbold P.G.
        • Brayshaw P.A.
        • Price R.A.
        • et al.
        Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
        Eur J Nucl Med Mol Imaging. 2011; 38: 302-311
        • Claringbold P.G.
        • Turner J.H.
        Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-octreotate-capecitabine- temozolomide radiopeptide chemotherapy.
        Neuroendocrinology. 2016; 103: 432-439
        • Ballal S.
        • Yadav M.P.
        • Damle N.A.
        • et al.
        Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumours: a long-term outcome, toxicity, survival, and quality-of-life study.
        Clin Nucl Med. 2017; 42: e457-e466
        • Satapathy S.
        • Mittal B.R.
        • Sood A.
        • et al.
        Peptide receptor radionuclide therapy as first-line systemic treatment in advanced inoperable/metastatic neuroendocrine tumors.
        Clin Nucl Med. 2020; 45: e393-e399
        • Satapathy S.
        • Mittal B.R.
        • Sood A.
        • et al.
        177Lu-DOTATATE plus radiosensitizing capecitabine versus octreotide long-acting release as first-line systemic therapy in advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors: a single-institution experience.
        JCO Glob Oncol. 2021; 7: 1167-1175